(Q53890877)

22 May 2018

title

Kallikrein 4 is associated with paclitaxel resistance in ovarian cancer. (English)

1 reference

22 May 2018

1 reference

1 reference

6

Claes Tropé

1 reference

22 May 2018

author name string

Zhijun Xi

1

1 reference

22 May 2018

Janne Kaern

2

1 reference

22 May 2018

Ben Davidson

3

1 reference

22 May 2018

Tove Irene Klokk

4

1 reference

22 May 2018

Bjørn Risberg

5

1 reference

22 May 2018

Fahri Saatcioglu

7

1 reference

22 May 2018

language of work or name

English

0 references

publication date

1 July 2004

1 reference

22 May 2018

published in

Gynecologic Oncology

1 reference

22 May 2018

volume

94

1 reference

22 May 2018

issue

1

1 reference

22 May 2018

page(s)

80-85

1 reference

22 May 2018

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.044

Stage at diagnosis of ovarian cancer in the United States, 1992-1997

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.044

Chemotherapy for ovarian cancer--a consensus statement on standard practice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.044

Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.044

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.044

Bcl-2 down-regulation is a novel mechanism of paclitaxel resistance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.044

Multidrug resistance gene-1 is a useful predictor of Paclitaxel-based chemotherapy for patients with ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.044

A role for loss of p53 function in sensitivity of ovarian carcinoma cells to taxanes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.044

Overexpression of kallikrein 10 in epithelial ovarian carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.044

Human kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.044

Human kallikrein 6 (zyme/protease M/neurosin): a new serum biomarker of ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.044

Molecular cloning and characterization of prostase, an androgen-regulated serine protease with prostate-restricted expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.044

Localization of a new prostate-specific antigen-related serine protease gene, KLK4, is evidence for an expanded human kallikrein gene family cluster on chromosome 19q13.3-13.4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.044

An efficient procedure for cloning hormone-responsive genes from a specific tissue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.044

Tissue microarrays for high-throughput molecular profiling of tumor specimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.044

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.044

Reporting results of cancer treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.044

Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.044

Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.044

Kallikrein 4 is a predominantly nuclear protein and is overexpressed in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.044

Differential expression of trypsin in human ovarian carcinomas and low-malignant-potential tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.044

Distinctly different gene structure of KLK4/KLK-L1/prostase/ARM1 compared with other members of the kallikrein family: intracellular localization, alternative cDNA forms, and Regulation by multiple hormones

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.044

Taxol-requiring mutant of Chinese hamster ovary cells with impaired mitotic spindle assembly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.044

BAX protein expression and clinical outcome in epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.044

An association of Bcl-2 phosphorylation and Bax localization with their functions after hyperthermia and paclitaxel treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.044

p53 expression and resistance against paclitaxel in patients with metastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.044

Estrogen increases intracellular p26Bcl-2 to p21Bax ratios and inhibits taxol-induced apoptosis of human breast cancer MCF-7 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.044

10.1016/J.YGYNO.2004.03.044

7 January 2021

Identifiers

DOI

1 reference

22 May 2018

1 reference

22 May 2018